Which patients should be included (e.g., pre-clinical, SCD, mild AD, MCI)? Should disease controls be included (e.g., PD, FTD)? Should patients with known risk factors (e.g., APOE positive) be included? What is the appropriate balance of ethnicities, geographic diversity, and genders? What is the appropriate cohort size? What is the minimum level of characterization required (e.g., neuropsychological tests, PET imaging, blood, CSF biomarkers)? How should a diversity of languages and accents be incorporated?
| Which types of speech samples should be collected? Consider spanning cognitive domains and cognitive load levels. Are the tests active or passive? How are the tests categorized (e.g., constrained, non-constrained)? Which speech sample collection tests will be best to characterize a patient’s disease progression? Per disease stage? Which tests will be most applicable to real-world settings?
| What is the appropriate frequency and duration of test administration? Will the setting of data collection (in-clinic or remote) impact patient compliance? Can tests be refined/adjusted over time if needed? How can annotation and collection be consistently ensured? How can broad data sharing and access be facilitated while ensuring patient privacy?
|
